News

Category:
|
February 9, 2021

Dewpoint profiled in Nature review of condensate focused start-ups

A Nature review of condensate focused start-ups has described Dewpoint as the “field’s frontrunner’. The article has profiled three condensate focused biotech’s, and discusses the importance of condensate modification as the next big hope for drug discovery.

Read more on nature.com

Media Contact

Jeanette Bressi
VP, Head of Communications & PR
Dewpoint Therapeutics
+1 609-439-3997 | jbressi@dewpointx.com

Investor Contact

Scott Peterson, Ph.D.
SVP, Corporate Development and Investor Relations
Dewpoint Therapeutics
speterson@dewpointx.com
Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
USA
© 2019-2023 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science